FDA Fast-Tracks EMD Serono MS Drug

Published July 28, 2010

FDA fast-tracks EMD Serono MS drug
EMD Serono, which is developing an oral tablet for the treatment of Multiple Sclerosis, has received a priority review by the U.S. Food and Drug Administration.
Read more on Mass High Tech: The Journal of New England Technology

Allos Therapeutics’ Folotyn meets study goal
Allos Therapeutics Inc. said Wednesday its drug Folotyn met key goals in a midstage study on lung cancer patients. The drug is already approved as a treatment for relapsed or refractory peripheral T-cell lymphoma, a type of cancer that attacks the immune system.
Read more on AP via Yahoo! Finance